Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers.

Human gene therapy - 1 Mar 2000

Hafkemeyer P, Licht T, Pastan I, Gottesman M M

Abstract excerpt

Cancers are frequently chemoresistant because of overexpression of P-glycoprotein. Two different approaches to improve cancer treatment are currently being investigated in clinical trials: inhibition of P-glycoprotein function by reversing agents, and alleviation of leukocytopenia by MDR1 gene transfer to normal bone marrow of patients. We report here that retroviral vectors encoding a mutant P-glycoprotein...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1
Share to Bone Marrow Cells

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Daunorubicin

Share to Gene Transfer Techniques

Share to Genetic Vectors

Share to K562 Cells

Share to Retroviridae

Share to Vincristine

Source

Identifiers

PMID: 10724034
DOI: 10.1089/10430340050015743

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers.PMID 10724034Read ↗

Mechanisms of drug resistance in hematologic malignancies.Semantic proximity Read ↗

Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expressionSemantic proximity Read ↗

Dual agent chemoprotection by retroviral co-expression of either MDR1 or MRP1 with the P140K mutant of O6-methylguanine-DNA-methyl transferase.Semantic proximity Read ↗

Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells.Semantic proximity Read ↗

Evaluation of multidrug resistant phenotype by flow cytometry with monoclonal antibodies and functional tests.Semantic proximity Read ↗

Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.Semantic proximity Read ↗

Clinical trials of agents that reverse multidrug resistance. A literature review.Semantic proximity Read ↗

Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators.Semantic proximity Read ↗

Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistanceSemantic proximity Read ↗

Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer.Semantic proximity Read ↗

Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.Semantic proximity Read ↗

Sensitization of multidrug-resistant human leukemia cells with MDR1-targeted antisense and inhibition of drug-mediated MDR1 induction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.